Treatment strategies for Legionella infection

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 7, 2009, Pages 1109-1121

  Luisa Pedro Botet, M ^b   Yu, Victor L ^a,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^c Special Pathogens Laboratory   (United States)

Author keywords

Animal model; Azithromycin; Clarithromycin; Community acquired pneumonia; Erythromycin; Hospital acquired pneumonia; Legionella; Legionella pneumophila; Legionnaires' disease; Levofloxacin; Macrolides; Quinolones; Rifampin; Tetracyclines

Indexed keywords

AZITHROMYCIN; CEFOXITIN; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; DOXYCYCLINE; DRINKING WATER; ERYTHROMYCIN; FLEROXACIN; GEMIFLOXACIN; GENTAMICIN; IMMUNOSUPPRESSIVE AGENT; JOSAMYCIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PAZUFLOXACIN; PEFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; ROXITHROMYCIN; SPARFLOXACIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE; TIGECYCLINE; TROVAFLOXACIN; UNINDEXED DRUG; ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; BACTERIUM CULTURE; BACTERIUM IDENTIFICATION; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MODEL; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERBILIRUBINEMIA; LEGIONELLA; LEGIONELLA URINARY ANTIGEN TEST; LEGIONNAIRE DISEASE; LIVER FUNCTION TEST; LOW DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; OTOTOXICITY; PHLEBITIS; REVIEW; SIDE EFFECT; SYMPTOM; URINALYSIS; ANIMAL; DRUG COMBINATION; DRUG EFFECT; LEGIONELLA PNEUMOPHILA; MICROBIOLOGICAL EXAMINATION;

ANIMALS; ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; HUMANS; LEGIONELLA PNEUMOPHILA; LEGIONNAIRES' DISEASE; MICROBIAL SENSITIVITY TESTS;

EID: 67649519192     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560902900820     Document Type: Review

References (112)

1. Fraser DW, Tsai T, Orenstein W, et al. Legionnaires' disease: description of an epidemic of pneumonia. N Engl J Med 1977;297:1189-1197 (Pubitemid 8226679)
2. Fraser DW, Wachsmuth I, Bopp C, et al. Antibiotic treatment of guinea-pigs infected with agent of Legionnaires' disease. Lancet 1978;1:175-178 (Pubitemid 8273521)
3. Horwitz MA, Silvertein SC. Intracellular multiplication of Legionnaires' disease bacteria (Legionella pneumophila) in human monocytes is reversibly inhibited by erythromycin and rifampin. J Clin Invest 1983;71:15-26 (Pubitemid 13170233)
4. Sabria M, Pedro-Botet L, Yu VL. Legionella species [cited 2009; Mar 30]. Available from: www.antimicrobe.org. Yu VL, Weber R, Raoult D editors, ESun Technologies, 2008;.
5. Edelstein PH, Edelstein MA. In vitro extracellular and intracellular activities of clavulanic acid and those of piperacillin and ceftriaxone alone and in combination with tazobactam against clinical isolates of Legionella species. Antimicrob Agents Chemother 1994;38:200-204 • Antimicrobial agent activity against intracellular L. pneumophila was classified into three major groups: those agents allowing significant growth, those allowing no significant growth but static in nature, and those that significantly reduced the bacterial concentration (bactericidal).
6. Vildé JL, Dournon E, Rajagopalan P. Inhibition of Legionella pneumophila multiplication within human macrophages by antimicrobial agents. Antimicrob Agents Chemother 1986;30:743-748 (Pubitemid 17187705)
7. Nowicki M, Paucod JC, Bornstein N, et al. Comparative efficacy of five antibiotics on experimental airborne legionellosis in guinea pigs. J Antimicrob Chemother 1988;22:513-519 (Pubitemid 18264820)
8. Johnson DM, Erwin ME, Barrett MS, et al. Antimicrobial activity of ten macrolide, lincosamine and streptogramin drugs tested against Legionella species. Eur J Clin Microbiol Infect Dis 1992;11:751-755
9. Pasculle AW, Dowling JN, Frola FN, et al. Antimicrobial therapy of experimental Legionella micdadei pneumonia in guinea pigs. Antimicrob Agents Chemother 1985;28:730-734 (Pubitemid 16196904)
10. Edelstein PH, Weiss WJ, Edelstein MA. Activities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2003;47(2):533-540 (Pubitemid 36158078)
11. Tanaseanu C, Bergallo C, Teglia O, et al. 308 Study Group; 313 Study Group. Integrated results of 2 phase 3 studies comparing togecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 2008;61:329-338
12. Stout JE, Sens K, Mietzner S, et al. Comparative activity of quinolones, macrolides and ketolides against Legionella species using in vitro broth dilution and intracellular susceptibility testing. Int J Antimicrob Agents 2005;25:302-307 • The rank order of intracellular activity from high to low against L. pneumophila serogroup 1 was quinolones > ketolides > macrolides. (Pubitemid 40387275)
13. Horwitz MA. Toward and understanding of host and bacterial molecules mediating L. pneumophila pathogenesis. In: Barbaree JM, Breiman RF, Dufour AP, editors. Legionella: current status and emerging perspectives. American Society for Microbiology. Washington, DC,1993;55-62
14. Fitzgeorge RB, Featherstone ASR, Baskerville A. Efficacy of azithromycin in the treatment of guinea pigs infected with Legionella pneumophila by aerosol. J Antimicrob Chemother 1990;25(Suppl A):101-108 (Pubitemid 20043955)
15. Fitzgeorge RB, Lever S, Baskerville A. A comparison of the efficacy of azithromycin and clarithromycin in oral therapy of experimental airborne Legionnaires' disease. J Antimicrob Chemother 1993;31:171-176 (Pubitemid 23220202)
16. Engleberg NC, McClain MS, Legendre M, Brieland JK. Macrolide-azalide efficacy against chronic pulmonary legionellosis in BALB/c gamma interferon knock-out mice abstract # A39. 97th Annual Meeting Of Amer Soc Microbiol, Miami Beach 1997
17. Stout JE, Arnold B, Yu VL. Comparative activity of azithromycin, clarithromycin, roxithromycin, dirithromycin, quinopristin/dalfopristin, and erythromycin against Legionella species by broth microdilution and intracellular susceptibility testing in HL-60 cells. J Antimicrob Chemother 1998;41:289-291 (Pubitemid 28083136)
18. Brieland JK, Loenbenberg D, Menzel F, Hare RS. Efficacy of SCH27899 in an animal modelo f Legionnaires' disease using immunocompromised A/J mice. Antimicrob Agents Chemother 2000;44:1333-1336 (Pubitemid 30228314)
19. Dubois J, St Pierre C. In vitro activity, postantibiotic effect and human monocyte activity of grepafloxacin against Legionella species. Clin Microbiol Infect 1999;5:205-212
20. Edelstein PH, Edelstein MAC. In vitro activity of the ketolide HMR 3647 (RU6647) for Legionella spp., its pharmacokinetics in guinea pigs with Legionella pneumophila pneumonia. Antimicrob Agents Chemother 1999;43:90-95
21. Kitsukawa K, Hara J, Saito A. Inhibition of Legionella pneumophila in guinea pig peritoneal macrophages by new quinolones, macrolide, and other antimicrobial agents. J Antimicrob Chemother 1991;27:343-353
22. Saito A, Sawatari K, Fukuda Y, et al. Susceptibility of Legionella pneumophila to ofloxacin in vitro and in experimental Legionella pneumonia in guinea pigs. Antimicrob Agents Chemother 1985;28:15-20 (Pubitemid 15029684)
23. Nielsen K, Hindersson P, Hoiby N, Bangsborg JM. Sequencing of the rpoB gene in Legionella pneumophila and characterization of mutations associated with rifampin resistance in the legionellaceae. Antimicrob Agents Chemother 2000;44:2679-2683 (Pubitemid 30737682)
24. Edelstein PH, Edelstein MA, Lehr KH, Ren J. In-vitro activity of levofloxacin against clinical isolates of Legionella spp., its pharmacokinetics in guinea pigs, and use in experimental Legionella pneumophila pneumonia. J Antimicrob Chemother 1996;37:117-126 (Pubitemid 26123140)
25. Edelstein PH, Edelstein MA, Ren J, et al. Activity of trovafloxacin CP-99, 219. against Legionella isolates: In vitro activity, intracellular accumulation and killing in macrophages, and pharmacokinetics and treatment of guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 1996;40:314-331
26. Edelstein PH, Edelstein MA, Weindenfeld J, Dorr MB. In vitro activity of sparfloxacin CI-978;AT-4140. for clinical Legionella isolates, pharmacokinetics in guinea pigs, and use to treat guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 1990;34:2122-2127
27. Baltch AL, Bopp LH, Smith RP, et al. Antibacterial activities of gemifloxacin, levofloxacin, gatifloxacin, moxifloxacin and erythromycin against intracellular Legionella pneumophila and Legionella micdadei in human monocytes. J Antimicrob Chemother 2005;56:104-109 (Pubitemid 41418342)
28. Edelstein PH, Shinzato T, Doyle E, Edelstein MAC. In vitro activity of gemifloxacin (SB-265805, LB20304a) against Legionella pneumophila and its pharmacokinetics in guinea pigs with L. pneumophila pneumonia. Antimicrob Agents Chemother 2001;45:2204-2209
29. Tano E, Cars O, Löwdin E. Pharmacodynamic studies of moxifloxacin and erythromycin against intracellular Legionella pneumophila in an in vitro kinetic model. J Antimicrob Chemother 2005;56:240-242 (Pubitemid 41418366)
30. Baltch AL, Smith RP, Franke MA, Michelsen PB. Antibacterial effects of levofloxacin, erythromycin, and rifampin in a human monocyte system against Legionella pneumophila. Antimicrob Agents Chemother 1998;42:3153-3156 (Pubitemid 28553734)
31. Manzor O, Majithia D, Saravolatz L. In vitro activities of seven quinolones and two macrolides against Legionella isolates. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, California USA, September 26-29. 1999
32. Jung R, Li DH, Pendland SL, Danziger LH. Intracellular activity of ABT-773 and other antimicrobial agents against Legionella pneumophila isolates. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, California USA, September 26-29. 1999
33. Saito A, Gaja M. In vitro and in vivo activities of sparfloxacin in Legionella infections. Drugs 1995;49(Suppl2):250-252
34. Saito A, Koga H, Shigeno H, et al. The antimicrobial activity of ciprofloxacin against Legionella species and the treatment of experimental Legionella pneumonia en guinea pigs. J Antimicrob Chemother 1986;18:251-260 (Pubitemid 16038796)
35. Kuzman I, Oreskovicic K, Schowald S, Culig S. Azithromycin in the treatment of community-acquired LD abstract number 10.29. Fourth International Conference on the macrolides, azalides, streptogramins, and ketolides, Barcelona, Jan 21-23, 1999
36. Kuzman I, Soldo I, Schonwald S, Culig J. Azithromycin for treatment of community-acquired pneumonia caused by Legionella pneumophila: a retrospective study. Scand J Infect Dis 1995;27:503-505
37. Myburgh J, Nagel GJ, Petschel E. The efficacy and tolerance of a three-day course of azithromycin in the treatment of community-acquired pneumonia. J Antimicrob Chemother 1993;31(Suppl E):163-169 (Pubitemid 23220201)
38. Plouffe J. Azithromycin IV/PO. For treatment of community-acquired pneumonia caused by Legionella pneumophila. The fifth International Conference on the macrolides, azalides, streptogramins, ketolides, and oxazolidinones; Seville, Spain. Hanuary 26-28, 2000
39. Sanchez F, Mensa J, Martinez JA, et al. Treatment of pneumonia caused by Legionella with azithromycin. Rev Esp Quimio 1998;11:147-151 (Pubitemid 28412725)
40. Vergis EN, Indorf A, File TM, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med 2000;160:1294-1300 (Pubitemid 30252775)
41. Blazquez-Garrido RM, Espinosa Parra FJ, Alemany Francés L, et al. Antimicrobial chemotherapy for Legionnaires' disease: levofloxacin versus macrolides. Clin Infect Dis 2005;40:800-6 •• Monotherapy with levofloxacin was a safe and effective treatment for Legionnaires' disease, including in patients with severe disease. In these patients, levofloxacin appeared to be more effective than clarithromycin.
42. Mykietiuk A, Carratalà J, Fernández-Sabé N, et al. Clinical outcomes for hospitalized patients with Legionella pneumonia in the antigenuria era: the influence of levofloxacin therapy. Clin Infect Dis 2005;40:794-799 (Pubitemid 40365496)
43. Sabrià M, Pedro-Botet ML, Gómez J, et al. For the Legionnaires' disease therapy group. Fluoroquinolones versus macrolides in the treatment of Legionnaires' disease. Chest 2005;128:1401-1405
44. Falcó V, Molina I, Juste C, et al. Tratamiento de la neumonía por Legionella pneumophila. Macrólidos o quinolonas? Enferm Infecc Microbiol Clin 2006;24:360-364 (Pubitemid 44133180)
45. Haranaga S, Tayetama M, Higa F, et al. Intravenous ciprofloxacin versus erythromycin in the treatment of Legionella pneumonia. Intern Med 2007;46:353-357 (Pubitemid 46585473)
46. Drusano G, Lebro MT, Cars O, et al. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Microbiol Infect 1998;4:2S27-2S41 (Pubitemid 28209760)
47. Salord JM, Matsiota-Bernard P, Staikowski F, et al. Unsuccessful treatment of Legionella pneumophila infection with a quinolone. Clin Infect Dis 1993;17:518-519 (Pubitemid 23261480)
48. Unertl KE, Lenhart FP, Forst H, et al. Ciprofloxacin in the treatment of legionellosis in critically ill patients including those cases unresponsive to erythromycin. Am J Med 1989;87(Suppl):128S-131S (Pubitemid 20005164)
49. Kurz RW, Graninger W, Egger TP, et al. Failure of treatment of Legionella pneumophila with ciprofloxacin. J Antimicrob Chemother 1988;22:389-391 (Pubitemid 18227123)
50. Yu VL, Greenberg RN, Zadeikis N, et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 2004;125(6):2135-2139 (Pubitemid 38788181)
51. Roig J, Rello J. Legionella: state of the art 30 years after its recognition. In: Cianciotto NP, Kwaik Y, Edelstein PS, et al, editors. Treatment of Legionnaires' disease. Washington, D.C.: American Society for Microbiology; 2006. p. 8-14
52. Meyer RD, Edelstein PH, Kirby BD, et al. Legionnaires' disease: unusual clinical and laboratory features. Ann Intern Med 1980;93(2):240-243 (Pubitemid 10044704)
53. Baltch AL, Smith RP, Ritz W. Inhibitory and bactericidal activities of levofloxacin, ofloxacin erythromycin, and rifampin used singly and in combination against Legionella pneumophila. Antimicrob Agents Chemother 1995;39:1661-1666
54. Moffie BG, Mouton RP. Sensitivity and resistance of Legionella pneumophila to some antibiotics and combinations of antibiotics. J Antimicrob Chemother 1988;22:457-462 (Pubitemid 18264813)
55. Dournon E, Mayaud C, Wolff M, et al. Comparison of the activity of three antibiotic regimens in severe Legionnaires' disease. J Antimicrob Chemother 1990;26(Suppl B):129 (Pubitemid 20382089)
56. Hubbard RB, Mathur RM, Mac Farlane JT. Severe community-acquired Legionella pneumonia: treatment, complications and outcome. Q J Med 1993;86:327-332 (Pubitemid 23160833)
57. Grau S, Mateu-de Antonio J, Ribes E, et al. Impact of rifampin addition to clarithromycin in Legionella pneumophila pneumonia. Int J Antimicrob Agents 2006;28:249-52 • In an observational study, combination therapy of clarithromycin and rifampin had no additional benefit compared with clarithromycin monotherapy. The length of stay might have been prolonged owing to possible negative drug interactions. We note that liver function test abnormalities, especially hyperbilirubinemia, are common and reversible. In our opinion, short courses of rifampin may still be useful.
58. Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999;37:385-398
59. Wallace RJ Jr, Brown BA, Griffith DE, et al. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium - M. intracellulare infection. J Infect Dis 1995;171:747-750
60. Peloquin CA, Berning SE. Evaluation of the drug interaction between clarithromycin and rifampin. J Infect Dis Pharmacother 1996;2:19-35 (Pubitemid 27203393)
61. Barker JE. Farrell ID. The effects of single and combined antibiotics on the growth of Legionella pneumophila using time-kill studies. J Antimicrob Chemother 1990;26:45-53 (Pubitemid 20263695)
62. Martin SJ, Pendland SL, Chen C, et al. In vitro synergy testing of macrolide-quinolone combinations against 41 clinical isolates of Legionella. Antimicrob Agents Chemother 1996;40:1419-1421
63. Martin SJ, Pendland SL, Chen C, et al. In vitro activity of clarithromycin alone and in combination with ciprofloxacin against Legionella spp.: enhanced effect by the addition of the metabolite 14-hydroxy clarithromycin. Diagn Microbiol Infect Dis 1997;29:167-171
64. Smith RP, Baltch AL, Franke M, et al. Effect of levofloxacin, erythromycin or rifampin pre-treatment on growth of Legionella pneumophila in human monocytes. J Antimicrob Chemother 1997;40:673-678 (Pubitemid 27503998)
65. Havlichek D, Saravolatz L, Pohlod D. Effect of quinolones and other antimicrobial agents on cell-associated Legionella pneumohila. Antimicrob Agents Chemother 1987;31:1529-1534 (Pubitemid 17140806)
66. Pohlod D, Saravolatz LD, Somerville MM. Inhibition of Legionella pneumophila multiplication within human macrophages by fleroxacin. J Antimicrob Chemother 1988;22(Suppl D):49-54 (Pubitemid 18264837)
67. Havlichek D, Pohlod D, Saravolatz L. Comparison of ciprofloxacin and rifampicin in experimental Legionella pneumophila pneumonia. J Antimicrob Chemother 1987;20:875-881 (Pubitemid 18033970)
68. Trubel HK, Meyer HG, Jahn B, et al. Complicated nosocomial pneumonia due to Legionella pneumophila in an immunocompromised child. Scand J Infect Dis 2002;34:219-221 (Pubitemid 34303068)
69. Stroup JS, Hendrickson SE, Neil M. Legionella pneumonia and HIV infection: a case report. AIDSRead 2004;14:267-271 (Pubitemid 38656231)
70. Ishii Y, Bando M, Ohno S, Sugiyama Y. A travel abroad-associated case of Legionella pneumonia diagnosed by urinary antigen detection test. Kansenshogaku Zasshi 2005;79:290-293
71. Oguma A, Kojima T, Himeji D, et al. A case of Legionella pneumonia complicated with acute respiratory distress syndrome treated with methylprednisolone and sivelestat sodium in combination with intravenous erythromycin and ciprofloxacin. Nihon Kokyuki Gakkai Zasshi 2004;42:956-960
72. Okano Y, Motoki T, Miki M, et al. A case of Legionella pneumonia successfully treated intravenously with both erythromycin and ciprofloxacin. Nihon Kokyuki Gakkai Zasshi 2001;39:949-954
73. Pedro-Botet ML, García-Cruz A, Tural C, et al. Severe Legionnaires' disease successfully treated with levofloxacin and azithromycin. J Chemother 2006;18:559-561 (Pubitemid 44776170)
74. Chidiac C, Pires-Croneberger S, Brun-Buisson C, et al. Antibiotic therapy for Legionnaires' disease: results of a French study in 595 hospitalized patients. #L-915 (abstract). In: ICAAC/IDSA Annual Meeting, Washington, D.C., October 2008
75. Jacobson KL, Miceli MH, Tarrand JJ, Kontoyiannis DP. Legionella pneumonia in cancer patients. Medicine (Baltimore) 2008;87(3):152-159 (Pubitemid 351769910)
76. García-Fulguerias A, Navarro C, Fenoll D, et al. Legionnaires' disease outbreak in Murcia, Spain. Emerg Infect dis 2003;9:915-953
77. Greig JA, Carnie JA, Grahan FT, et al. An outbreak of Legionnaires' disease at the Melbourne Aquarium, April 2000: investigation and case-control studies. MAJ 2004;180:566-572
78. Kirby BS, Snyder KM, Meyer RD, Finegold SM. Legionnaires' disease: report of sixty-five nosocomially acquired cases and review of the literature. Medicine (Baltimore) 1980;59:188-205 (Pubitemid 10117855)
79. Marston BJ, Lipman HB, Breiman RF. Surveillance for Legionnaires' disease: risk factors for morbidity and mortality. Arch Intern Med 1994;154:2417-2422 (Pubitemid 2153855)
80. Bollin GE, Plouffe JF, Para MF, Prior RB. Difference in virulence of environmental isolates of Legionella pneumophila. J Clin Microbiol 1985;21:674-722 (Pubitemid 15093112)
81. Dennis PJ, Lee JV. Differences in aerosol survival between pathogenic and non pathogenic strains of Legionella pneumophila serogroup 1. J Appl Bacteriol 1988;65:135-141 (Pubitemid 18271908)
82. Summergill JT, Raff MJ, Miller RD. Interaction of virulent and avirulent Legionella pneumophila with human monocytes. J Leukoc Biol 1990;47:31-38 (Pubitemid 20015314)
83. Roig J, Rello J. Legionnaires' disease: a rational approach to therapy. J Antimicrob Chemother 2003;16:145-151
84. Health CH, Grove DI, Looke DFM. Delay in appropriate therapy of Legionella pneumonia associated with increased mortality. Eur J Clin Microbiol Infect Dis 1996;15:286-290 (Pubitemid 26159688)
85. Gacouin A, Le Tulzo Y, Lavoue S, et al. Severe pneumonia due to Legionella pneumophila: prognostic factors, impact of delayed appropriate antimicrobial therapy. Intensive care Med 2002;28:686-691 (Pubitemid 34639478)
86. Pedro-Botet ML, Sabria-Leal M, Sopena N, et al. Role of immunosuppression in the evolution of Legionnaires' disease. Clin Infect Dis 1998;26:14-19 • This study showed a trend between complications and basal immunosuppression with patients on immunosuppressive therapy having the highest mortality. (Pubitemid 28068150)
87. Chow JW, Yu VL. Legionella: a major opportunistic pathogen in transplant recipients. Seminars in Respiratory Infections 1998;13:132-139 (Pubitemid 28268629)
88. Pedro-Botet ML, Sabrià M, Sopena N, et al. Legionnaires' disease and HIV infection. Chest 2003;124:543-547 • Legionnaires' disease had a more severe clinical presentation and worse evolution in patients with HIV. (Pubitemid 37000131)
89. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336(4):243-250 (Pubitemid 27044625)
90. Lim WS, van der Erden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-382 (Pubitemid 36560938)
91. Feldman C, Alanee S, Yu VL, et al. Severity of illness scores in patients with bacteremic pneumococcal pneumonia: implications for ICU care. European Respiratory Society. Abstract 1851, Berlin, 8 October 2008
92. Matsumoto N, Mukae H, Yamashita S, et al. A case of severe Legionnaires' disease complicated by rhabdomyolysis, acute renal failure, liver dysfunction and encephalopathy. Kansenshogaku Zasshi 2000;74:989-993
93. Kawai A, Kawai A, Nakajima H, et al. Surviving case of Legionella pneumonia showing a high level of serum Il-6 and complicated with rhabdomyolysis. Nihon Kokyuki Gakkai Zasshi 2004;42:737-742
94. Nozue T, Chikazawa H, Miyanishi S, et al. Legionella pneumonia associated with adult respiratory distress syndrome caused by Legionella pneumophila serogroup 3. Intern Med 2005;44:73-78 (Pubitemid 40260046)
95. Bodur H, Savran Y, Koca U, et al. Legionella pneumonia with acute respiratory distress syndrome, myocarditis and septic shock successfully treated with drotrecogin alpha (activated). Eur J Anaesthesiol 2006;23:808-810 (Pubitemid 44195817)
96. Narita Y, Naoki K, Horiuchi N, et al. A case of Legionella pneumonia associated with acute respiratory distress syndrome (ARDS) and acute renal failure treated with methylprednisolone and sivelestat. Nihon Kokyuki Gakkai Zasshi 2007;45:413-418
97. Neil K, Berkelman R. Increasing incidence of legionellosis in the United States, 1990-2005: changing epidemiologic trends. Clin Infect Dis 2008;47(5):591-599 •• The US Centers for Disease Control and Prevention have noticed a substantial increase of reported legionellosis cases in recent years, particularly in the eastern United States and among middle-aged adults. They recommend that Legionella infection be considered in the differential diagnosis of any patient with pneumonia.
98. Health Protection Agency, United Kingdom. National increase in Legionnaires' disease. 03 Aug 2007
99. Mulazimoglu L, Yu VL. Can Legionnaires disease be diagnosed by clinical criteria? A critical review. Chest 2001;120:1049-1053 •• Classic clinical manifestations of Legionnaires' disease may be nonspecific, such that milder cases are overlooked. (Pubitemid 32960067)
100. Yu VL, Ramirez J, Roig J, Sabria M. Legionnaires disease and the updated IDSA guidelines for community-acquired pneumonia. Clin Infect Dis 2004;39:1734-1737
101. Yu VL, Stout JE. Community-acquired legionnaires disease: implications for underdiagnosis and laboratory testing. Clin Infect Dis 2008;46:1365-1367 (Pubitemid 351589934)
102. von Baum H, Ewig S, Marre R, et al. Community Acquired Pneumonia Study Group. Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia. Clin Infect Dis 2008;46:1356-1364 •• The German multicenter study of the Competence Network for Community-Acquired Pneumonia (CAPNETZ) confirmed that clinical manifestations are not useful in predicting the likelihood of Legionella pneumonia and that a rapid laboratory test for determining the etiology of the pneumonia should be performed for CAP patients. Legionella was a common cause of community-acquired pneumonia. Ten per cent of community-acquired cases were caused by other species or serogroups not detectable by the urinary antigen test. There was an unacceptably high rate of inadequate initial antimicrobial treatment.
103. Greenberg D, Chiou CC, Famigilieti R, Lee TZ. Problem pathogens: paediatric legionellosis - implications for improved diagnosis. Lancet Infect Dis 2006;6:529-535 •• Awareness of Legionella as a potential cause of pediatric pneumonia is particularly important because antimicrobial therapy, often used for empirical therapy in children, is not effective against Legionella. (Pubitemid 44093338)
104. Pedro-Botet ML, Sopena N, Tudela P, et al. Should Legionella urinary antigen test be applied in any case of community-acquired pneumonia? 18th European Congress of infectious Diseases and Clinical Microbiology [abstract 033]. Barcelona, Spain, 19-22 April 2008
105. Lettinga KD, Verbon A, Weverling GJ, et al. Legionnaires' disease at a Dutch flower show: prognostic factors and impact of therapy. Emerg Infect Dis 2002;8:1448-1454 (Pubitemid 36008783)
106. Sabria M, Mòdol JM, Garcia-Nuñez M, et al. Environmental cultures and hospital-acquired Legionnaires' disease: a 5-year prospective study in 20 hospitals in Catlonia, Spain. Infect Control Hosp Epidemiol 2004;25:1072-1076 •• A 20-hospital prospective study in Catalonia, Spain, showed that routine environmental cultures of the hospital drinking water led to the discovery of hospital-acquired Legionnaires' disease. (Pubitemid 39664735)
107. Stout JE, Muder RR, et al. Role of environmental surveillance in determining the risk of hospital-acquired legionellosis: a National Surveillance Study with Clinical Correlations. Infect Control Hosp Epidemiol 2007;28:818-824 •• A 20-hospital prospective study in the United States showed that routine environmental cultures of hospital drinking water led to the discovery of hospital-acquired Legionnaires' disease. None of the hospitals had experienced known cases of Legionnaires' disease prior to the study. (Pubitemid 47055921)
108. Yu VL. Resolving the controversy on environmental cultures for Legionella: a modest proposal. Infect Control Hosp Epidemiol 1998;19:893-897
109. Garcia de Lomas J, Millas E, Lazaro MA, et al. A comparative study on the efficacy of the new quinolone alatrofloxacin in the treatment of experimental legionellosis in guinea pigs. Eur J Clin Microbiol Infect Dis 1998;17:420-423 (Pubitemid 28427364)
110. Dournon E, Rajagopalan P, Vidle JL, Pocidalo JJ. Efficacy of pefloxacin in comparison with erythromycin in the treatment of experimental guinea pig legionellosis. J Antimicrob Chemother 1986;17(Suppl B):41-48
111. Tzianabos AO, Rodgers FG. Pathogenesis and chemotherapy of experimental Legionella pneumophila infection in the chick embryo. Zentralbl Bakteriol 1989;271:293-303 (Pubitemid 19242182)
112. Pedro-Botet L, Yu VL. Legionella: macrolides or quinolones? Clin Microbiol Infect 2006;12(Suppl 3):25-30 •• Dosage of quinolones should be maximal. Macrolides and quinolones are the drugs of choice. In four observational studies totalling 458 patients, mortality was similar for both macrolides (erythromycin and clarithromycin, but not azithromycin) and quinolones (levofloxacin, ofloxacin, ciprofloxacin). Clinical response was more rapid for quinolones.